Authors:
Amit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis, Diana Rasoulouniriana, Asaf Madi, Chen Luxenburg, Jonathan Cohen, Krishnanand Padmanabhan, Noam Shomron, Guy Shapira, Annette Gleiberman, Roma Parikh, Carmit Levy, Meora Feinmesser, Dov Hershkovitz, Valentina Zemser-Werner, Oran Zlotnik, Sanne Kroon, Wolf-Dietrich Hardt, Reno Debets, Nathan Edward Reticker-Flynn, Peleg Rider, Yaron Carmi
Understanding The Limitations Of Immunotherapy Checkpoint Inhibition
While checkpoint inhibition Immunotherapy has been advertised as the future of Oncology, the underlying reality is that this class of interventions against cancer, suffers from many of the same systemic failures as Chemotherapy.
Notably, tumor cells can evade Immunotherapy by generating unique transient cell-in-cell structures, which are resistant to killing by both T cells and Chemotherapies.
As such, the ability of tumor cells to transiently enter and disseminate from each other in response to T-cell killing is a biological process that has never been described heretofore. It better explains how immunogenic tumors can survive in the host and provides a novel framework for Immunotherapies.
コメント